Common Contracts
3 similar Employment Agreement contracts by Immunocore Holdings PLC, Immunocore LTD
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 28th, 2024 • Immunocore Holdings PLC • Biological products, (no disgnostic substances) • Pennsylvania
This Amended and Restated Employment Agreement (the “Agreement”) is entered into by and between Brian Di Donato (“Executive”) and Immunocore, LLC, a Delaware limited liability company and an indirect wholly owned subsidiary of Immunocore Holdings Limited, a company incorporated under the laws of England and Wales to be renamed as Immunocore Holdings Plc after its re-registration as a public limited company (hereinafter referred to together as the “Company”) and is effective as of, and contingent upon, the occurrence of the “IPO Date” (as defined in the Immunocore Holdings Plc 2021 Equity Incentive Plan (the “Plan”)) (the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 28th, 2024 • Immunocore Holdings PLC • Biological products, (no disgnostic substances) • Maryland
This Amended and Restated Employment Agreement (the “Agreement”) is entered into by and between David Berman (“Executive”) and Immunocore, LLC, a Delaware limited liability company and an indirect wholly owned subsidiary of Immunocore Holdings Limited, a company incorporated under the laws of England and Wales to be renamed as Immunocore Holdings Plc after its re-registration as a public limited company (hereinafter referred to together as the “Company”) and is effective as of, and contingent upon, the occurrence of the “IPO Date” (as defined in the Immunocore Holdings Plc 2021 Equity Incentive Plan (the “Plan”)) (the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 1st, 2021 • Immunocore LTD • Biological products, (no disgnostic substances) • Maryland
This Amended and Restated Employment Agreement (the “Agreement”) is entered into by and between Bahija Jallal (“Executive”) and Immunocore, LLC, a Delaware limited liability company and an indirect wholly owned subsidiary of Immunocore Holdings Limited, a company incorporated under the laws of England and Wales to be renamed as Immunocore Holdings plc after its re-registration as a public limited company (hereinafter referred to together as the “Company”) and is effective as of, and contingent upon, the occurrence of the “IPO Date” (as defined in the Immunocore Holdings plc 2021 Equity Incentive Plan (the “Plan”)) (the “Effective Date”).
